

Summary of achievements 2014–2021

The European & Developing Countries Clinical Trials Partnership



Investments in calls for proposals



• Investment to call for proposals by year

• Cumulative investment to call for proposals by year

(Indicative amounts based on signed grant agreements and proposals approved for funding)

EDCTP investments in R&D

Clinical studies €684.50 M

to support 140 collaborative research projects with large-scale clinical trials and other clinical research activities conducted by European-African consortia.

Total funding €814.30 M for 431 projects awarded to date.



Clinical research capacity €85.47 M


to support **90 projects** that strengthen the enabling environment for conducting clinical trials and clinical research.

Participation in

EDCTP-funded activities:

Fellowship programme €44.33 M

to support 201 fellowships projects that focus on the career development of African scientists.



Medical interventions

Collaborative research projects by disease



- Tuberculosis, 33 grants €194.83 M
- Malaria, 17 grants €136.47 M
- HIV & HIV-associated infections, 20 grants €113.05 M
- Emerging diseases, 37 grants €77.61 M
- Neglected infectious diseases, 19 grants €70.60 M
- Diarrhoeal diseases, 6 grants €51.19 M
- Lower respiratory tract infections, 8 grants €40.75 M

Collaborative research projects by intervention



- Vaccines, 26 grants €243.05 M
- Diagnostics, 47 grants €121.32 M
- Non-intervention specific topics, 9 grants €31.90 M
- Product-focused implementation research, 7 grants €6.22 M

327 is the total number of clinical studies awarded by EDCTP since 2014. Of these, 64% (210) are interventional (clinical trials) studies of drugs and vaccines, diagnostic testing and evaluation studies, and 35% (117) are non-interventional studies (observational studies of drugs and vaccines, diagnostics and prognostics, and other studies).

Research centres and clinical trial sites involved in clinical research

38 sub-Saharan African countries host recruitment sites of EDCTP-funded collaborative clinical studies.

63% (88) of clinical trials are phase II and III studies of drugs and vaccines aiming to deliver key evidence on safety and efficacy. The phase III




Clinical trials of drugs and vaccines by phase

registration.

17% (24) of the trials involve

post-license (phase IV) studies aiming to influence health policies and practice, and optimise the delivery of medical interventions for the widerange of sub-Saharan African health systems and diverse populations.




Population in clinical studies

11% (33) of all studies target

Eswatini(1

pregnant women and their children. Other key populations are also involved in the studies, such as newborns and infants (70; 24%), children (100; 34%) and adolescents (96; 33%).






Epidemic preparedness and response


€13.11 M invested to support 27 projects in sub-Saharan Africa aiming to manage and/ or prevent the spread of the current COVID-19 outbreak.

COVID-19 research response is also carried out by the two consortia, PANDORA-ID-NET and ALERRT, funded by EDCTP through earlier investments of €20 M in epidemic preparedness research. A total of **105 institutions** from **12 countries** in Europe and **26 countries** in sub-Saharan Africa participate in EDCTP's COVID-19 projects. Fourteen projects are coordinated by entities based in sub-Saharan Africa.

Collaboration and capacity development

EDCTP projects involve **305** sub-Saharan African institutions. These account for **60%** of total EDCTP funding.






18 sub-Saharan African

countries are members of the EDCTP Association. In the EDCTP 2014-2020 work plans, 16 African members have submitted **120 Participating States'** Initiated Activities (PSIAs) of total committed value of ≤ 67 M. **201 fellows** from 24 African countries are supported with the potential to become research leaders. Furthermore, EDCTP has supported **534 trainees** on EDCTP projects from 33 sub-Saharan African countries (including 197 Master's and 208 PhD students).






Trainees on EDCTP grants by type



Gender equality in science

158 of the projects in the EDCTP2 portfolio are led by a female:



Of the **408 academic trainings** (Bachelor's, Master's and PhD) of African researchers, **317** (78%) are pursued at academic institutions in Africa.

150 epidemiologists and **biostatisticians** across Africa funded through an EDCTP-Africa CDC joint initiative. 0

39% of the members of expert review committees for EDCTP calls evaluations are female.

46% of the 534 African academic trainees are female.

European coordination



14 European countries are members of the EDCTP Association. In the EDCTP 2014-2020 work plans, these members have submitted 301 Participating States' Initiated Activities (PSIAs) of total committed value of **€ 1.157 billion**. PSIAs are research activities within the scope of the EDCTP programme that are funded and implemented by one or more member countries.

€175.43 M is the total cash received from the European member countries to the EDCTP programme.

Partnerships



15% (338 out of 2231) of all

participations in EDCTP-funded projects involve private-sector institutions.

They include private not-for-profit entities (245 or 11%) such as foundations and product development partnerships, private-for-profit institutions (29 or 1%) such as pharmaceutical companies and small-and-medium enterprises (64 or 3%).


Private sector institutions were awarded €176.30 M by EDCTP in 2021.

€27.79 M has been leveraged from partners for the launch of joint or coordinated calls for proposals.

Partner contributions to joint initiatives launched with EDCTP




European member countries cash contribution to the EDCTP programme



€384.66 M has been leveraged as co-funding to EDCTP projects through the EDCTP strategic calls for proposals (€276.13 M in cash and €108.53 M in-kind).

Co-funding in EDCTP projects (top 5 funders)



The EDCTP2 programme is supported under Horizon 2020, the European Union's Framework Programme for Research and Innovation.



